Skip to main content
. 2020 Jan 27;24(5):2993–3021. doi: 10.1111/jcmm.14934

Figure 5.

Figure 5

DFS and OS of patients for the SII by ER status with breast cancer. A, Kaplan‐Meier analysis of DFS of patients by ER negative with breast cancer in core needle biopsy. B, Kaplan‐Meier analysis of OS of patients by ER negative with breast cancer in core needle biopsy. C, Kaplan‐Meier analysis of DFS of patients by ER positive with breast cancer in core needle biopsy. D, Kaplan‐Meier analysis of OS of patients by ER positive with breast cancer in core needle biopsy. E, Kaplan‐Meier analysis of DFS of patients by ER negative with breast cancer in post‐operative pathology IHC. F, Kaplan‐Meier analysis of OS of patients by ER negative with breast cancer in post‐operative pathology IHC. G, Kaplan‐Meier analysis of DFS of patients by ER positive with breast cancer in post‐operative pathology IHC. H, Kaplan‐Meier analysis of OS of patients by ER positive with breast cancer in post‐operative pathology IHC